WARNING: This product is strictly for Research Use Only (RUO). It is not intended for human consumption, diagnostic application, or therapeutic use. All information below is provided for educational and laboratory research purposes only.
Selank peptide is a synthetic regulatory heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Originally engineered as a stabilized analog of the endogenous immunopeptide Tuftsin, Selank has become a widely studied compound in experimental neuroscience due to its anxiolytic, nootropic, and neurotrophic properties.
Unlike classical anxiolytic agents that directly stimulate inhibitory receptors and induce sedation, Selank operates through indirect neuromodulatory pathways. Preclinical research indicates that Selank influences GABAergic signaling, monoamine balance, enkephalin metabolism, and neurotrophin expression without impairing cognitive performance. This positions Selank as a valuable research tool for studying stress resilience, neuroplasticity, and neurotransmitter homeostasis.
Chemical Structure and Tuftsin Lineage
Selank is structurally derived from Tuftsin (Thr-Lys-Pro-Arg), a naturally occurring tetrapeptide fragment of the Fc region of human immunoglobulin G (IgG). Tuftsin is known for its immunomodulatory properties but demonstrates limited stability and poor penetration of the blood–brain barrier (BBB).
To overcome these limitations, Selank incorporates a C-terminal Pro-Gly-Pro (PGP) tripeptide extension. This modification significantly increases metabolic stability and enhances resistance to serum peptidases. The PGP sequence also contributes to improved central nervous system availability, allowing Selank to exert measurable effects within brain tissue following intranasal or systemic administration in animal models.
- Peptide Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro
- Molecular Weight: ~751.9 Da
- CAS Number: 129954-34-3
- Classification: Tuftsin analog / regulatory peptide
Mechanism of Action: GABAergic System Modulation
One of the most extensively studied properties of Selank peptide is its influence on the GABAergic neurotransmitter system. Importantly, Selank does not bind directly to the benzodiazepine site of the GABA(A) receptor. Instead, it functions as a positive allosteric modulator, altering receptor sensitivity and gene expression rather than forcing ion channel activation.
This distinction is critical in experimental models, as Selank produces anxiolytic-like effects without sedation, muscle relaxation, or amnesic outcomes typically associated with benzodiazepines. Behavioral assays in rodents consistently demonstrate reduced anxiety-related behaviors while preserving locomotion and learning capacity.
Transcriptomic Regulation of Neurotransmission
Beyond receptor-level modulation, Selank induces rapid changes at the genetic level. A transcriptomic study conducted by Volkova et al. (2016) analyzed gene expression in the rat frontal cortex following Selank administration.
The results revealed significant modulation of genes associated with inhibitory neurotransmission:
- 52 GABA-related genes exhibited altered expression
- 45 genes were regulated within one hour of administration
- Targets included receptor subunits, transporters, and ion channel regulators
These findings suggest that Selank initiates a systems-level rebalancing of neuronal excitability rather than acting as a single-receptor ligand. This genomic mechanism may explain the sustained behavioral effects observed in experimental models despite the peptide’s relatively short plasma presence.
Effects on Neurotrophins: BDNF and TrkB Signaling
Selank peptide also exerts a significant influence on neurotrophic signaling pathways, particularly those involving Brain-Derived Neurotrophic Factor (BDNF). BDNF is a key regulator of synaptic plasticity, learning, memory, and neuronal survival.
Experimental data indicates a time-dependent mechanism:
- Transcriptional Phase: Increased Bdnf mRNA expression detected approximately 3 hours post-administration.
- Translational Phase: Elevated BDNF protein levels observed 24 hours after administration.
Additionally, Selank upregulates the expression of TrkB receptors, enhancing neuronal sensitivity to BDNF signaling. This coordinated increase in ligand and receptor availability suggests a durable neuroplastic response rather than a transient biochemical effect.
Regulation of Enkephalins and Monoamine Balance
Selank has been shown to inhibit enzymes responsible for the degradation of endogenous opioid peptides, particularly leucine-enkephalin. By suppressing enkephalinase activity, Selank prolongs the presence of endogenous enkephalins, contributing to stress reduction and emotional stabilization in animal models.
In parallel, Selank modulates monoamine neurotransmitters:
- Serotonin: Increased turnover correlating with improved mood regulation.
- Dopamine: Preservation of dopamine levels under stress and hypoxic conditions.
- Norepinephrine: Normalization of stress-induced catecholamine spikes without suppressing baseline alertness.
Rather than forcing neurotransmitter elevation or suppression, Selank appears to promote homeostatic balance, a property highly relevant to research on chronic stress and anxiety disorders.
Experimental Research Contexts
Selank peptide has been investigated across multiple experimental paradigms, including:
- Anxiety and stress-response models
- Ethanol withdrawal and memory impairment
- Hypoxia-induced cognitive dysfunction
- Age-related decline in synaptic plasticity
In these models, Selank consistently demonstrates neuroprotective and cognition-preserving effects without evidence of tolerance, dependence, or immunogenicity during long-term administration.
Conclusion
Selank peptide represents a sophisticated regulatory molecule for experimental neuroscience research. By combining transcriptomic modulation, GABAergic stabilization, neurotrophin upregulation, and endogenous peptide preservation, Selank provides a multifaceted platform for studying anxiety regulation, neuroplasticity, and neurotransmitter balance.
Its unique mechanism—distinct from classical anxiolytics—makes Selank particularly valuable for laboratory investigations into non-sedating neuroprotective strategies and long-term synaptic health.
At PeptidesSkin.com, this content is provided to support laboratory researchers, academic professionals, and institutions seeking reliable scientific information on regulatory peptides used exclusively for research purposes.
References
- Volkova, A. et al. (2016). Transcriptomic effects of Selank on GABAergic signaling in rat brain. Neuroscience and Behavioral Physiology.
- Kolik, L. et al. (2019). Selank prevents ethanol-induced cognitive impairment via BDNF regulation. Neurochemical Journal.
- Ashmarin, I. et al. (2005). Regulatory peptides: Mechanisms of action and therapeutic potential. Peptides.
- PubMed Central – Selank peptide and neurotrophic signaling studies.